Hangzhou Yingbairui Biomedical

Hangzhou Yingbairui Biomedical (Inno-PRB) is a clinical-stage biotechnology company based in China, specializing in the development of innovative cell therapies for cancer. The company focuses on its proprietary CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy platform, which aims to provide "off-the-shelf" treatments for both solid tumors and hematological malignancies. Their lead programs include IBR733, a CAR-NK therapy targeting CD73, and IBR822, targeting GPC3 for liver cancer. In addition to NK cell therapies, Yingbairui is advancing CAR-T and bispecific antibody programs to address unmet medical needs in oncology.